Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2025
The treatment landscape for ulcerative colitis (UC) is evolving rapidly, driven by the introduction of novel therapies and shifting prescribing patterns. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade and AbbVie’s Humira), a cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s Stelara) are the mainstays of treatment, followed by oral targeted therapies comprising Janus kinase (JAK) inhibitors (Pfizer’s Xeljanz / Xeljanz XR and AbbVie’s Rinvoq). However, later-to-market drugs, such as sphingosine 1-phosphate receptor (S1P-R) modulators (Bristol Myers Squibb’s Zeposia and Pfizer’s Velsipity) and IL-23 inhibitors (Eli Lilly’s Omvoh, AbbVie’s Skyrizi, Johnson & Johnson Innovative Medicine’s Tremfya), are increasing the competition among later-line targeted therapies. The availability of infliximab biosimilars and adalimumab biosimilars in the United States are further impacting market dynamics.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult UC patients?
- How have Omvoh and Skyrizi been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of adult UC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Market covered: United States
Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Pfizer, Takeda, UCB, BMS
Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz / Xeljanz XR, Simponi, Zeposia, Rinvoq, Omvoh, Skyrizi, aminosalicylates, immunosuppressants
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
